Membership

August 2012

Dear Colleagues: 

We hope that those of you who have enjoyed summer season have had a good and healthy vacation period! 

Many new things have recently happened within IASLC; 

IASLC has now been approved as a CME provider! That is a significant achievement for our organization and gives our Educational department much more flexibility in planning future activities. 

The Board of Directors has after long time of explorations and many considerations decided that the World Conferences from year 2016 will be annual meetings. With that the WLCCs will rotate every year between the three regions; North America, Europe and the rest of the world. IASLC is currently exploring which cities in the different regions are most suitable for hosting the WLCCs, and the previous local committees will now be replaced by regional committees. 

The IASLC is still working on establishing regional offices; the first one will be located in Asia in order to better support activities in that region. 

In 2014 the IASLC will officially turn 40 years old! The 40 years celebration will include many activities and will go through the next few years. For the occasion of the 40 years celebration, the Board of Directors decided to establish a new young investigator fellowship in order to strengthen the development of the next generation investigators in thoracic malignancies. The BOD decided to designate this fellowship in Professor Heine H. Hansen’s name (below). We hope as many as possible will support the establishment of this fellowship. 

The IASLC Council of Regents has just appointed a new chair: Professor Gail Darling, MD, from Toronto (see below). 

The IASLC regional Meetings continue to be successful. The Latin-American Lung Cancer Conference was recently held in Rio de Janeiro, Brazil with 550 participants. The Asian Pacific Lung Cancer Meeting will be held in Fukuoka, 

Japan in November 2012 (see below), and the IASLC/ASTRO/ASCO/University of Chicago Multidisciplinary Conference will be held in Chicago September 6-8. 2012 (see below). 

We hope that as many as possible will participate in the regional meetings, which all have exciting scientific programs covering the whole spectrum of science and current management of thoracic malignancies. 

Fred R. Hirsch, MD, PhD 

Editor, IASLC Newsletter 

IASLC Chief Executive Officer 

The International Association for the Study of Lung Cancer (IASLC) has opened its search for candidates for Chief Executive Officer (CEO). The CEO serves as the leader of the IASLC, representing the organization in all internal and external activities. The CEO reports to the President and the Board of Directors and is responsible for ensuring that the IASLC activities set by the Board are carried out. The CEO is responsible for ensuring that the IASLC reaches the mission, goals and strategic plan set forth by the Board of Directors. 

The CEO is responsible for providing strategic leadership for the IASLC by working with the Board of Directors and the management team to establish long-range goals, strategies, plans and policies in support of the IASLC mission to: 

  • Promote the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies; 
  • Disseminate information about lung cancer and other thoracic malignancies to the members of the Association, to the medical community at large, and to the public; and, 
  • Use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.  

The IASLC Executive offices are located in Aurora, Colo. It is expected that the CEO will spend at least 75 percent effort in his/her role of CEO of the IASLC. With Board approval, the CEO may spend the remainder of his/her working week in other academic/clinical positions related to thoracic oncology. This may include a part time appointment in an academic or other institution approved by the Board. The CEO must be in regular contact with the Executive Office, but may live and have an academic appointment at a location outside of Colorado and the USA with Board approval. 

Principal Duties 

1. Works effectively with the Board to support the IASLC’s mission, goals and strategic plan. 

2. Works with the Board to develop, monitor and revise the strategic plan. 

3. Works with the Board and staff to secure funding and sponsorship for all IASLC activities. 

4. Provides leadership and management to ensure that the mission, vision and core values of the IASLC are developed, communicated and implemented. 

5. Responsible for leading the IASLC to achieve and surpass membership, educational, research and financial goals and objectives. 

6. Spearheads the development, communication and implementation of effective growth strategies and processes. 

7. Collaborates with the management team to develop and implement plans for the operational infrastructure of systems, processes and personnel designed to accommodate the growth objectives of the IASLC. 

8. Motivates and leads a high-performance management team, attracts, recruits and retains required staff and provides appropriate mentoring for their success. 

9. Represents the IASLC with members, donors and other partners. 

10. Establishes credibility throughout the IASLC and with the Board of Directors as an effective developer of solutions to management, mission and other challenges. 

11. Fosters a success-oriented, accountable environment within the organization. 

12. Oversees the IASLC activities of the COO/CFO and other staff. 

Position Requirements 

The CEO is expected to be a physician member of the IASLC and who has a career focus on thoracic oncology. More than 10 years of experience in oncology activities, leadership activities and administrative activities are required. 

To perform the job successfully, an individual should demonstrate the following competencies to perform the essential functions of this position. 

  • Leadership— proven success in leading, inspiring, motivating, and managing other professionals; personal creativity and strategic vision, coupled with an ability to listen to others and learn from their best ideas; 
  • Management skills— demonstrated ability to inspire trust, organize people into effective teams and motivate them to work well together; includes staff in planning, decision-making, facilitating and process 
  • improvement; makes self available to staff; provides regular performance feedback; and develops subordinates’ skills and encourages growth; 
  • Delegation—delegates work assignments and gives authority to work independently; sets expectations and monitors delegated activities; 
  • Demonstrated management acumen— proven record in maintaining or increasing organizational viability and effectiveness, and comfort in dealing with the budgeting process and management of staff and financial resources; 
  • Demonstrated fundraising ability, particularly with individuals, endowments and foundations and a willingness to try new ideas in fundraising; 
  • Judgment—displays a willingness to make decisions, exhibits sound and accurate judgment, and makes timely decisions; 
  • Communications—communicates clearly and persuasively, both orally and in writing, in positive or negative situations; demonstrates group presentation skills and conducts productive meetings; 
  • Analytical—synthesizes complex and diverse information; 
  • Problem solving—identifies and resolves problems in a timely manner and gathers and analyzes information skillfully; 
  • Quality management—looks for ways to improve and promote quality and demonstrates accuracy and thoroughness; 
  • Planning/organizing—prioritizes and plans work activities, uses time efficiently and develops realistic action plans. 

Minimum Qualifications 

1. Must be a physician member in good standing in the IASLC. 

2. Demonstrated effectiveness with interpersonal and public relations essential. 

3. High level of attention to planning, execution and details. 

4. Must be experienced with international meetings of all sizes. 

5. Must possess the ability to balance the needs and desires of multiple constituencies and cultures. 

6. Must exhibit great diplomacy in guiding members and leaders from varying cultures and languages, and with diverse agendas and skill levels, to agree on the most logical and beneficial actions that will ensure the success of IASLC and the achievement of its mission.  

7. Leadership experience in nonprofit or philanthropic organizations such as service on the executive, board or committee member, preferably having served in several elected or appointed offices at international level. 

8. Requires proficiency in English and experience with presentations to audiences of varying sizes and make-up. 

9. Should be seen as a recognized leader within the field of lung cancer/thoracic malignancies research and treatment. 

Inquiries and submissions should be sent to: 

IASLC Search Committee 

Send documents electronically to: IASLC@KornFerry.com 

More information can be found on the IASLC website, www.iaslc.org 

Submission should be delivered by Sept. 15, 2012 and include a letter of interest, a one- to two-page vision statement, a curriculum vitae and a plan of how to effectively engage and manage IASLC staff in Denver. 

2012 Chicago Multidisciplinary Symposium in Thoracic Oncology, September 6-8, 2012

Register online through August 24; register on site in Chicago after that 

IASLC to Host Satellite Symposium/Breakfast Meeting at Chicago Multidisciplinary Symposium – September 7 from 6:30 am to 7:30 am 

For those attending the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology (September 6-8), the IASLC is hosting a Satellite Symposium on Friday morning, September 7 from 6:30 am to 7:30 am in the Chicago Marriott Downtown Magnificent Mile. It will be held in the Grand Ballroom on the 7th floor. Please join Chairman David Gandara, MD and a multidisciplinary faculty as they address the Critical Questions concerning Molecular Testing for Non-Small Cell Lung Cancer. Registration is on-site. 

5th APLCC ITMIG IASLC Conference, November 26-28, 2012 

IASLC is now a CME Provider 

The International Association for the Study of Lung Cancer (IASLC) has been awarded Provisional Accreditation as a Continuing Medical Education (CME) provider by the Accreditation Council for Continuing Medical Education (ACCME). 

A two-year term of Provisional Accreditation is the highest award possible for initial applicants such as the IASLC. IASLC was found to fulfill all accreditation requirements set forth by ACCME and is certified as a CME provider from July 2012 until July 31, 2014. 

In memoriam: Yoshihiro Hayata 

 

With deep sadness, the IASLC received the message that one of the pioneers of lung cancer research, Prof. Yoshihiro Hayata (1924-2012) passed away in Tokyo on August 22, 2012. Prof. Yoshihiro Hayata was the President of IASLC (1991-1994) and organized WCLC2000 in Tokyo as the Meeting President. He worked in Tokyo Medical University for 20 years (1969-1989) as Professor of Surgery. He established in vitro lung cancer cell lines in 1973, one of which is widely used EGFR-mutation positive PC-9, as well as the development of canine lung cancer model for further researches. He also developed photodynamic therapy for early stage central type lung cancer. He began the lung cancer screening program in Tokyo in 1978. He attracted many young investigators because of his scientific attitude and warm personality. 

IASLC 40th Anniversary Professor Heine H. Hansen Fellowship

As we embark on the next 40 years of the International Association for the Study of Lung Cancer, we pause to celebrate the past 40 years. The IASLC Board of Directors commemorates this notable time in the IASLC history by a 40th Anniversary Campaign to raise money for an additional fellowship in order to strengthen our education of the next generation lung cancer investigators. This fellowship will be named in Professor Heine H. Hansen’s honor. Professor Hansen was instrumental in the development of the IASLC. He was Congress President of the 2nd World Conference on Lung Cancer in Copenhagen in 1980. He served on the Board of Directors from 1985 to 1994 and served as the President from 1988-1991. Prof. Hansen was the first Executive Director of the IASLC (1991-2001) and was also the founder of the first IASLC journal Lung Cancer in 1985. He was a leader in developing international guidelines for the staging and treatment of small cell lung cancer and arranged many international workshops in this field. He received the IASLC Merit Award in 1997 and became the first Honorary Member in 2003. The IASLC fellowships benefit young researchers with the intention of encouraging innovative research in lung cancer prevention and translational medicine worldwide. Board members have made significant contributions to kick off this campaign. Please show your commitment to the IASLC 40th Anniversary Campaign by contributing to the Professor Heine H. Hansen Fellowship. 

Heine H. Hansen, M.D., Ph.D. (1938-2011)

Name: ________________________________________________________

Commitment Amount: USD 1,000 500 100 50 Other __________

Send payments to: IASLC

13100 E. Colfax Ave Unit 10

Aurora, CO 80011 

IASLC Web-based Education Programs 

NOW AVAILABLE FROM THE IASLC WEBINAR SERIES: 

In 2011, the Journal for Thoracic Oncology published the “International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma,” issued by a multidisciplinary team of lung cancer specialists. To better understand the general implications of this new classification, and the issues affecting specific specialties, please join us for this On-Demand Webinar Series. 

Module 1 - Introducing The New IASLC/ATS/ERS Lung Adenocarcinoma Classification

Module 2 - Implications of the New IASLC/ATS/ERS Classification; Module 3 - Highlights for the Pathologist; Module 4 - Highlights for the Radiologist; Module 5 - Case Studies for the Practicing Clinician 

Please go to www.iaslc.org for more details 

Women and Lung Cancer - CME-certified Audio-guided Web course 

The International Association for the Study of Lung Cancer (IASLC) has partnered with joint sponsors Penn State College of Medicine and Rockpointe to bring a CME-certified webcourse to oncologists caring for patients with lung cancer. 

Click here to view activity: http://rockpointe.com/?prgId=118

Please remember to pay your 2012 IASLC membership fee - $200 

Registering online is fast and easy! Visit www.iaslc.org/membership for more information. 

IASLC members will be sent renewal reminders and invoices. Register now so there will no interruption to your JTO subscription, and to receive discounts on 2012 meeting fees. Please contact the Membership Department if you need any assistance paying your dues: Pamela.goens@iaslc.org 

IASLC Staging Manual: 

The IASLC Staging Manual and Handbook in Thoracic Oncologic has now surpassed 35,000 copies sold worldwide. In addition, the Staging Posters and Reference Cards continue to be popular reference aids of the 7th edition staging system for practitioners and tumor boards. IASLC members can continue to order these publications and products at special member pricing (www.iaslcpubs.org; contact info@iaslc-staging.org for further information). 

In addition, translations of these publications have been completed or are in process in multiple languages: Chinese, Italian, Japanese, Polish, and Turkish. Discussions about future translations in Spanish, Arabic, and Russian are ongoing. 

The new IASLC Staging Manual has been published in different formats. Several years of work from the IASLC Staging Committee and particularly the chair Dr. Peter Goldstraw, has resulted in a formal staging manual. The book and the “pocket-cards” can be ordered at www.iaslc.org 

 

 

 
iPhone/iPad Staging Atlas

 

www.jto.org

 

 

 

Names: 

David P. Carbone, MD, PhD has accepted a new position per September 1st, 2012 as Professor of Medicine and Director of the James Thoracic Center at Ohio State University, Columbus, OH. Dr. Carbone will be leaving his position as Director of Thoracic Program at Vanderbilt-Ingram Cancer Center. Dr. Carbone is currently serving as a member of IASLC BOD. 

 

 

 

 

 

Gail Darling, MD: New Chair of IASLC Council of Regents. 

Dr. Darling is Professor of Thoracic Surgery at the University of Toronto, Canada. She believes in a holistic approach to medicine, being involved in diagnostics, staging, surgery and coordinated care. She wants to follow her patients from beginning to end. It’s part of the reason she values membership in the IASLC. It’s a place she can build relationships with colleagues around the globe from different disciplines. She credits her mentors, Dr. Frances Shepherd and Dr. Michael Johnston for encouraging her to join the world-wide organization. An active member of the IASLC since 2001, Dr. Darling will take her involvement to a new level by serving as the Chair of the Council of Regents. Her contact information is gail.darling@uhn.on.ca 

Phone: 1 416 946 4573. 

 

 Announcement 

IASLC Election 2013 

In 2013, the IASLC will hold an election for a President-Elect from North America, a Treasurer and 8 new Board members (3 from North America, 3 from Europe, and 2 from Asia/Australia/South America/Africa). The Board of Directors has a total of 15 Directors, 5 each from North America, Europe, and 

Asia/Australia/South America/Africa. The Board of Directors should be diverse in terms of specialty and gender. Under current bylaws the terms of office are as follows: 

New members of the Board of Directors will be elected for a two-year period 2013-2015, potentially renewable for an additional term. The President-Elect will serve three terms (President-Elect, President and Past President). The Treasurer will serve up to two terms. 

The following board members will remain as elected members of the Board from 2013-2015. 

North America 

Alex Adjei, medical oncology 

Carolyn Dresler, surgery 

Europe 

Christian Manegold, medical oncology 

Silvia Novello, pulmonology 

Asia/Australia/South America/Africa 

Kazuhiko Nakagawa, medical oncology 

Sumitra Thongprasert, medical oncology 

Tetsuya Mitsudomi, surgery 

The Nominating Committee is seeking nominations for the President-Elect, Treasurer and Board seats. You are encouraged to nominate yourself and/or another IASLC member to one of these positions. 

An ideal candidate is one who is actively engaged in the IASLC and consistently attends the World Conference on Lung Cancer and/or other IASLC conferences, and willing to attend approximately four board meetings per year and to serve on IASLC Committees. 

Additional roles and responsibilities can be found on the IASLC website at http://www.iaslc.org/about-iaslc/nominations/ 

Nominations will begin on September 1 and close on November 30, 2012. 

To nominate an individual or to self-nominate, please go to the following website http://www.iaslc.org/about-iaslc/nominations/ to complete the application process. 

Upcoming IASLC Workshops/Meetings 2012- 2015 

Chicago Multidisciplinary Symposium in Thoracic Oncology 

September 6-8, 2012 

Location: Hotel Marriott, Chicago, Illinois, U.S.A. 

More information: pia.hirsch@ucdenver.edu 

3rd International Thoracic Oncology Congress 

Dresden, Germany 

September 13-15, 2012 

Contact: prof.manegold@t-online.de 

5th Asia Pacific Lung Cancer Conference 

November 26-28, 2012 Location: Hilton Sea Hawk, Fukuoka, Japan 

More information: nsaijo@med.kindai.ac.jp 

2013 

15th World Conference on Lung Cancer 

October 27-31, 2013 

Location: Sydney, Australia 

More information: pia.hirsch@ucdenver.edu 

2015 

16th World Conference on Lung Cancer 

September 4-8, 2015 

Location: Denver, Colorado, USA 

More information: pia.hirsch@ucdenver.edu 

RESEARCH PATHOLOGIST POSITION AVAILABLE: 

At The University of Colorado Cancer Center in Prof. Fred Hirsch’s Biomarker Laboratory, a position as a research pathologist is available. The position requires a licensed pathologist, but US license in not required. The laboratory is focusing on development and validation of biomarkers for new targeted therapies and early detection of lung cancer. Further information: Fred.Hirsch@ucdenver.edu